Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Status Recruiting

Clinical Trial Summary

The investigators explored the safety and activity of weekly irinotecan liposomes in patients with relapsed and metastatic Ewing Sarcoma.

Clinical Trial Description

After standard multimodal therapy, the prognosis of relapsed and metastatic Ewing Sarcoma is dismal and unchanged over the last decades. The anti-tumor activity of irinotecan was demonstrated by several studies in the past. However, longer schedule of irinotecan infusion (traditionally dx5x2) has impacted quality of life in these patients. The irinotecan liposomes may be more active than the parent compound irinotecan since its ability to stay longer in circulation system, and much more convenient to given weekly. Thus, the investigators explored the safety and activity of weekly irinotecan liposomes in patients with relapsed and metastatic Ewing Sarcoma after the failure of first-line chemotherapy with doxorubicin, vincristine, cyclophosphamide, ifosphamide and etoposide. Bayesian Optimal Interval (BOIN) design is adopted in this dose-finding study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06340204
Study type	Interventional
Source	Peking University People's Hospital
Contact
Status	Recruiting
Phase	Phase 1
Start date	March 25, 2024
Completion date	December 25, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00026780` - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Recruiting	`NCT06094101` - Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)	Phase 1/Phase 2
Recruiting	`NCT06029218` - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy	N/A
Completed	`NCT00743496` - A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma	Phase 1
Recruiting	`NCT04337177` - Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors	Phase 1
Active, not recruiting	`NCT02945800` - Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma	Phase 2
Recruiting	`NCT06156410` - Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma	Phase 1
Recruiting	`NCT05968768` - To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)	Phase 2
Terminated	`NCT02536183` - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors	Phase 1
Recruiting	`NCT03715933` - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Phase 1
Active, not recruiting	`NCT03220035` - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Completed	`NCT05093322` - A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT02856048` - Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer	Phase 2/Phase 3
Withdrawn	`NCT03880123` - Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma	Phase 1
Completed	`NCT04956198` - Drug Sensitivity and Mutation Profiling
Recruiting	`NCT04791228` - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors	Phase 2
Recruiting	`NCT06068075` - Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD	N/A
Active, not recruiting	`NCT03709680` - Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05734066` - Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma	Phase 1/Phase 2
Completed	`NCT02044120` - ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma	Phase 1